Biolase Profit Margin

The latest profit margin for BIOL is -34.84% as of September 2024. That compares with -50.17% in the prior-year period — up 30.6% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Biolase's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIOL's profit margin moved from -50.17% to -34.84% — a 30.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biolase's valuation or profitability profile.

Against Healthcare companies, BIOL currently prints -34.84% for profit margin, while the sector average sits near 21.34%. That is roughly 263.3% below the sector mean. Large gaps often invite a closer look at Biolase's growth, margins, and balance sheet.

Profit Margin shows how effectively Biolase converts resources into returns. At -34.84%, BIOL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -50.17% in the prior-year period — up 30.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BIOL's profit margin (-34.84%), review year-over-year change from -50.17%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.